

FIRST REGULAR SESSION

SENATE BILL NO. 516

99TH GENERAL ASSEMBLY

INTRODUCED BY SENATOR MUNZLINGER.

Read 1st time March 1, 2017, and ordered printed.

ADRIANE D. CROUSE, Secretary.

2262S.011

AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to schedules of controlled substances.

Be it enacted by the General Assembly of the State of Missouri, as follows:

Section A. Section 195.017, RSMo, is repealed and one new section
2 enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a
2 substance in Schedule I if it finds that the substance:

- 3 (1) Has high potential for abuse; and
- 4 (2) Has no accepted medical use in treatment in the United States or
5 lacks accepted safety for use in treatment under medical supervision.

6 2. Schedule I:

7 (1) The controlled substances listed in this subsection are included in
8 Schedule I;

9 (2) Any of the following opiates, including their isomers, esters, ethers,
10 salts, and salts of isomers, esters, and ethers, unless specifically excepted,
11 whenever the existence of these isomers, esters, ethers and salts is possible
12 within the specific chemical designation:

- 13 (a) Acetyl-alpha-methylfentanyl;
- 14 (b) Acetylmethadol;
- 15 (c) Allylprodine;
- 16 (d) Alphacetylmethadol;
- 17 (e) Alphameprodine;
- 18 (f) Alphamethadol;
- 19 (g) Alpha-methylfentanyl;

EXPLANATION—Matter enclosed in bold-faced brackets [thus] in this bill is not enacted and is intended to be omitted in the law.

- 20 (h) Alpha-methylthiofentanyl;
21 (i) Benzethidine;
22 (j) Betacetylmethadol;
23 (k) Beta-hydroxyfentanyl;
24 (l) Beta-hydroxy-3-methylfentanyl;
25 (m) Betameprodine;
26 (n) Betamethadol;
27 (o) Betaprodine;
28 (p) Clonitazene;
29 (q) Dextromoramide;
30 (r) Diampromide;
31 (s) Diethylthiambutene;
32 (t) Difenoxin;
33 (u) Dimenoxadol;
34 (v) Dimepheptanol;
35 (w) Dimethylthiambutene;
36 (x) Dioxaphetyl butyrate;
37 (y) Dipipanone;
38 (z) Ethylmethylthiambutene;
39 (aa) Etonitazene;
40 (bb) Etoxidine;
41 (cc) Furethidine;
42 (dd) Hydroxypethidine;
43 (ee) Ketobemidone;
44 (ff) Levomoramide;
45 (gg) Levophenacetylmorphan;
46 (hh) 3-Methylfentanyl;
47 (ii) 3-Methylthiofentanyl;
48 (jj) Morpheridine;
49 (kk) MPPP;
50 (ll) Noracetylmethadol;
51 (mm) Norlevorphanol;
52 (nn) Normethadone;
53 (oo) Norpipanone;
54 (pp) Para-fluorofentanyl;
55 (qq) PEPAP;

- 56 (rr) Phenadoxone;
57 (ss) Phenampromide;
58 (tt) Phenomorphan;
59 (uu) Phenoperidine;
60 (vv) Piritramide;
61 (ww) Proheptazine;
62 (xx) Properidine;
63 (yy) Propiram;
64 (zz) Racemoramide;
65 (aaa) Thiofentanyl;
66 (bbb) Tilidine;
67 (ccc) Trimeperidine;
68 (3) Any of the following opium derivatives, their salts, isomers and salts
69 of isomers unless specifically excepted, whenever the existence of these salts,
70 isomers and salts of isomers is possible within the specific chemical designation:
71 (a) Acetorphine;
72 (b) Acetyldihydrocodeine;
73 (c) Benzylmorphine;
74 (d) Codeine methylbromide;
75 (e) Codeine-N-Oxide;
76 (f) Cyprenorphine;
77 (g) Desomorphine;
78 (h) Dihydromorphine;
79 (i) Drotebanol;
80 (j) Etorphine (except hydrochloride salt);
81 (k) Heroin;
82 (l) Hydromorphanol;
83 (m) Methyldesorphine;
84 (n) Methyldihydromorphine;
85 (o) Morphine methylbromide;
86 (p) Morphine methylsulfonate;
87 (q) Morphine-N-Oxide;
88 (r) Myrophine;
89 (s) Nicocodeine;
90 (t) Nicomorphine;
91 (u) Normorphine;

- 92 (v) Pholcodine;
- 93 (w) Thebacon;
- 94 (4) Any material, compound, mixture or preparation which contains any
95 quantity of the following hallucinogenic substances, their salts, isomers and salts
96 of isomers, unless specifically excepted, whenever the existence of these salts,
97 isomers, and salts of isomers is possible within the specific chemical designation:
- 98 (a) 4-bromo-2, 5-dimethoxyamphetamine;
- 99 (b) 4-bromo-2, 5-dimethoxyphenethylamine;
- 100 (c) 2,5-dimethoxyamphetamine;
- 101 (d) 2,5-dimethoxy-4-ethylamphetamine;
- 102 (e) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 103 (f) 4-methoxyamphetamine;
- 104 (g) 5-methoxy-3,4-methylenedioxyamphetamine;
- 105 (h) 4-methyl-2, 5-dimethoxyamphetamine;
- 106 (i) 3,4-methylenedioxyamphetamine;
- 107 (j) 3,4-methylenedioxymethamphetamine;
- 108 (k) 3,4-methylenedioxy-N-ethylamphetamine;
- 109 (l) N-hydroxy-3, 4-methylenedioxyamphetamine;
- 110 (m) 3,4,5-trimethoxyamphetamine;
- 111 (n) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine, its isomers, salts,
112 and salts of isomers;
- 113 (o) Alpha-ethyltryptamine;
- 114 (p) Alpha-methyltryptamine;
- 115 (q) Bufotenine;
- 116 (r) Diethyltryptamine;
- 117 (s) Dimethyltryptamine;
- 118 (t) 5-methoxy-N,N-diisopropyltryptamine;
- 119 (u) Ibogaine;
- 120 (v) Lysergic acid diethylamide;
- 121 (w) Marijuana or marihuana;
- 122 (x) Mescaline;
- 123 (y) Parahexyl;
- 124 (z) Peyote, to include all parts of the plant presently classified botanically
125 as *Lophophora Williamsii* Lemaire, whether growing or not; the seeds thereof; any
126 extract from any part of such plant; and every compound, manufacture, salt,
127 derivative, mixture or preparation of the plant, its seed or extracts;

- 128 (aa) N-ethyl-3-piperidyl benzilate;
- 129 (bb) N-methyl-3-piperidyl benzilate;
- 130 (cc) Psilocybin;
- 131 (dd) Psilocyn;
- 132 (ee) Tetrahydrocannabinols naturally contained in a plant of the genus
- 133 Cannabis (cannabis plant), as well as synthetic equivalents of the substances
- 134 contained in the cannabis plant, or in the resinous extractives of such plant, or
- 135 synthetic substances, derivatives, and their isomers with similar chemical
- 136 structure and pharmacological activity to those substances contained in the plant,
- 137 such as the following:
- 138 a. 1 cis or trans tetrahydrocannabinol, and their optical isomers;
- 139 b. 6 cis or trans tetrahydrocannabinol, and their optical isomers;
- 140 c. 3,4 cis or trans tetrahydrocannabinol, and their optical isomers;
- 141 d. Any compounds of these structures, regardless of numerical designation
- 142 of atomic positions covered;
- 143 (ff) Ethylamine analog of phencyclidine;
- 144 (gg) Pyrrolidine analog of phencyclidine;
- 145 (hh) Thiophene analog of phencyclidine;
- 146 (ii) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
- 147 (jj) Salvia divinorum;
- 148 (kk) Salvinorin A;
- 149 (ll) Synthetic cannabinoids:
- 150 a. Any compound structurally derived from 3-(1-naphthoyl)indole or
- 151 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the
- 152 indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
- 153 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not
- 154 further substituted in the indole ring to any extent, whether or not substituted
- 155 in the naphthyl ring to any extent. Including, but not limited to:
- 156 (i) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole;
- 157 (ii) JWH-015, or 1-propyl-2-methyl-3-(1-naphthoyl)indole;
- 158 (iii) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;
- 159 (iv) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;
- 160 (v) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;
- 161 (vi) JWH-081, or 1-pentyl-3-(4-methoxy-1-naphthoyl)indole;
- 162 (vii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole;
- 163 (viii) JWH-122, or 1-pentyl-3-(4-methyl-1-naphthoyl)indole;

- 164 (ix) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole;
- 165 (x) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-naphthoyl)indole;
- 166 (xi) JWH-210, or 1-pentyl-3-(4-ethyl-1-naphthoyl)indole;
- 167 (xii) JWH-398, or 1-pentyl-3-(4-chloro-1-naphthoyl)indole;
- 168 b. Any compound structurally derived from 3-(1-naphthoyl)pyrrole by
- 169 substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
- 170 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
- 171 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole
- 172 ring to any extent, whether or not substituted in the naphthyl ring to any extent;
- 173 c. Any compound structurally derived from 1-(1-naphthylmethyl)indene
- 174 by substitution at the 3-position of the indene ring by alkyl, haloalkyl, alkenyl,
- 175 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
- 176 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene
- 177 ring to any extent, whether or not substituted in the naphthyl ring to any extent;
- 178 d. Any compound structurally derived from 3-phenylacetylindole by
- 179 substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl,
- 180 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
- 181 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole
- 182 ring to any extent, whether or not substituted in the phenyl ring to any
- 183 extent. Including, but not limited to:
- 184 (i) JWH-201, or 1-pentyl-3-(4-methoxyphenylacetyl)indole;
- 185 (ii) JWH-203, or 1-pentyl-3-(2-chlorophenylacetyl)indole;
- 186 (iii) JWH-250, or 1-pentyl-3-(2-methoxyphenylacetyl)indole;
- 187 (iv) JWH-251, or 1-pentyl-3-(2-methylphenylacetyl)indole;
- 188 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole;
- 189 e. Any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol
- 190 by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl,
- 191 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or
- 192 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring
- 193 to any extent. Including, but not limited to:
- 194 (i) CP 47, 497 & homologues, or 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-
- 195 methyloctan-2-yl)phenol), where side chain n=5, and homologues where side
- 196 chain n=4,6, or 7;
- 197 f. Any compound containing a 3-(benzoyl)indole structure with
- 198 substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl,
- 199 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl

200 or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the
201 indole ring to any extent and whether or not substituted in the phenyl ring
202 to any extent. Including, but not limited to:

- 203 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole;
- 204 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole;
- 205 g. CP 50, 556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-
206 phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]
207 acetate;
- 208 h. HU - 210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl -3-
209 (2-methyloctan -2-yl)-6a,7,10,10 a-tetrahydrobenzo[c]chromen-1-ol;
- 210 i. HU - 211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-
211 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo [c]chromen-
212 1-ol;
- 213 j. CP 50, 556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-
214 -phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl]
215 acetate;
- 216 k. Dimethylheptylpyran, or DMHP;
- 217 (5) Any material, compound, mixture or preparation containing any
218 quantity of the following substances having a depressant effect on the
219 central nervous system, including their salts, isomers and salts of isomers
220 whenever the existence of these salts, isomers and salts of isomers is
221 possible within the specific chemical designation:
- 222 (a) Gamma-hydroxybutyric acid;
- 223 (b) Mecloqualone;
- 224 (c) Methaqualone;
- 225 (6) Any material, compound, mixture or preparation containing any
226 quantity of the following substances having a stimulant effect on the
227 central nervous system, including their salts, isomers and salts of isomers:
- 228 (a) Aminorex;
- 229 (b) N-benzylpiperazine;
- 230 (c) Cathinone;
- 231 (d) Fenethylamine;
- 232 (e) 3-Fluoromethcathinone;
- 233 (f) 4-Fluoromethcathinone;
- 234 (g) Mephedrone, or 4-methylmethcathinone;
- 235 (h) Methcathinone;

- 236 (i) 4-methoxymethcathinone;
- 237 (j) (+,-) cis-4-methylaminorex ((+,-)cis-4,5-dihydro -4-methyl-5-
- 238 phenyl-2 -oxazolamine);
- 239 (k) Methylenedioxypropylone, MDPV, or (1-(1,3-Benzodioxol-5-yl)
- 240 -2-(1-pyrrolidinyl)-1-pentanone;
- 241 (l) Methylone, or 3,4-Methylenedioxypropylone;
- 242 (m) 4-Methyl-alpha-pyrrolidinobutylphenone, or MPBP;
- 243 (n) N-ethylamphetamine;
- 244 (o) N,N-dimethylamphetamine;
- 245 (7) A temporary listing of substances subject to emergency
- 246 scheduling under federal law shall include any material, compound,
- 247 mixture or preparation which contains any quantity of the following
- 248 substances:
- 249 (a) N-(1-benzyl-4-piperidyl)-N-phenylpropanamide (benzylfentanyl),
- 250 its optical isomers, salts and salts of isomers;
- 251 (b) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
- 252 (thenylfentanyl), its optical isomers, salts and salts of isomers;
- 253 (8) Khat, to include all parts of the plant presently classified
- 254 botanically as *catha edulis*, whether growing or not; the seeds thereof; any
- 255 extract from any part of such plant; and every compound, manufacture, salt,
- 256 derivative, mixture, or preparation of the plant, its seed or extracts.
- 257 3. The department of health and senior services shall place a
- 258 substance in Schedule II if it finds that:
- 259 (1) The substance has high potential for abuse;
- 260 (2) The substance has currently accepted medical use in treatment
- 261 in the United States, or currently accepted medical use with severe
- 262 restrictions; and
- 263 (3) The abuse of the substance may lead to severe psychic or physical
- 264 dependence.
- 265 4. The controlled substances listed in this subsection are included
- 266 in Schedule II:
- 267 (1) Any of the following substances whether produced directly or
- 268 indirectly by extraction from substances of vegetable origin, or
- 269 independently by means of chemical synthesis, or by combination of
- 270 extraction and chemical synthesis:
- 271 (a) Opium and opiate and any salt, compound, derivative or

272 preparation of opium or opiate, excluding apomorphine, thebaine-derived
273 butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone and naltrexone,
274 and their respective salts but including the following:

- 275 a. Raw opium;
- 276 b. Opium extracts;
- 277 c. Opium fluid;
- 278 d. Powdered opium;
- 279 e. Granulated opium;
- 280 f. Tincture of opium;
- 281 g. Codeine;
- 282 h. Ethylmorphine;
- 283 i. Etorphine hydrochloride;
- 284 j. Hydrocodone;
- 285 k. Hydromorphone;
- 286 l. Metopon;
- 287 m. Morphine;
- 288 n. Oxycodone;
- 289 o. Oxymorphone;
- 290 p. Thebaine;

291 (b) Any salt, compound, derivative, or preparation thereof which is
292 chemically equivalent or identical with any of the substances referred to in
293 this subdivision, but not including the isoquinoline alkaloids of opium;

294 (c) Opium poppy and poppy straw;

295 (d) Coca leaves and any salt, compound, derivative, or preparation
296 of coca leaves, and any salt, compound, derivative, or preparation thereof
297 which is chemically equivalent or identical with any of these substances,
298 but not including decocainized coca leaves or extractions which do not
299 contain cocaine or ecgonine;

300 (e) Concentrate of poppy straw (the crude extract of poppy straw in
301 either liquid, solid or powder form which contains the phenanthrene
302 alkaloids of the opium poppy);

303 (2) Any of the following opiates, including their isomers, esters,
304 ethers, salts, and salts of isomers, whenever the existence of these isomers,
305 esters, ethers and salts is possible within the specific chemical designation,
306 dextrorphan and levopropoxyphene excepted:

307 (a) Alfentanil;

- 308 (b) Alphaprodine;
309 (c) Anileridine;
310 (d) Bezitramide;
311 (e) Bulk dextropropoxyphene;
312 (f) Carfentanil;
313 (g) Dihydrocodeine;
314 (h) Diphenoxylate;
315 (i) Fentanyl;
316 (j) Isomethadone;
317 (k) Levo-alphaacetylmethadol;
318 (l) Levomethorphan;
319 (m) Levorphanol;
320 (n) Metazocine;
321 (o) Methadone;
322 (p) Meperidine;
323 (q) Methadone-Intermediate, 4-cyano-2-dimethylamino-4,4-
324 diphenylbutane;
325 (r) Moramide-Intermediate, 2-methyl-3-morpholino-1,
326 [1-diphenylpropane—carboxylic] **1-diphenylpropane-carboxylic acid**;
327 (s) Pethidine (meperidine);
328 (t) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
329 (u) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-
330 carboxylate;
331 (v) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-
332 carboxylic acid;
333 (w) Phenazocine;
334 (x) Piminodine;
335 (y) Racemethorphan;
336 (z) Racemorphan;
337 (aa) Remifentanil;
338 (bb) Sufentanil;
339 (cc) Tapentadol;
340 (3) Any material, compound, mixture, or preparation which contains
341 any quantity of the following substances having a stimulant effect on the
342 central nervous system:
343 (a) Amphetamine, its salts, optical isomers, and salts of its optical

344 isomers;

345 (b) Lisdexamfetamine, its salts, isomers, and salts of its isomers;

346 (c) Methamphetamine, its salts, isomers, and salts of its isomers;

347 (d) Phenmetrazine and its salts;

348 (e) Methylphenidate;

349 (4) Any material, compound, mixture, or preparation which contains

350 any quantity of the following substances having a depressant effect on the

351 central nervous system, including its salts, isomers, and salts of isomers

352 whenever the existence of those salts, isomers, and salts of isomers is

353 possible within the specific chemical designation:

354 (a) Amobarbital;

355 (b) Glutethimide;

356 (c) Pentobarbital;

357 (d) Phencyclidine;

358 (e) Secobarbital;

359 (5) Any material or compound which contains any quantity of

360 nabilone;

361 (6) Any material, compound, mixture, or preparation which contains

362 any quantity of the following substances:

363 (a) Immediate precursor to amphetamine and methamphetamine:

364 Phenylacetone;

365 (b) Immediate precursors to phencyclidine (PCP):

366 a. 1-phenylcyclohexylamine;

367 b. 1-piperidinocyclohexanecarbonitrile (PCC);

368 (7) Any material, compound, mixture, or preparation which contains

369 any quantity of the following alkyl nitrites:

370 (a) Amyl nitrite;

371 (b) Butyl nitrite.

372 5. The department of health and senior services shall place a

373 substance in Schedule III if it finds that:

374 (1) The substance has a potential for abuse less than the substances

375 listed in Schedules I and II;

376 (2) The substance has currently accepted medical use in treatment

377 in the United States; and

378 (3) Abuse of the substance may lead to moderate or low physical

379 dependence or high psychological dependence.

380 6. The controlled substances listed in this subsection are included
381 in Schedule III:

382 (1) Any material, compound, mixture, or preparation which contains
383 any quantity of the following substances having a potential for abuse
384 associated with a stimulant effect on the central nervous system:

- 385 (a) Benzphetamine;
- 386 (b) Chlorphentermine;
- 387 (c) Clortermine;
- 388 (d) Phendimetrazine;

389 (2) Any material, compound, mixture or preparation which contains
390 any quantity or salt of the following substances or salts having a
391 depressant effect on the central nervous system:

392 (a) Any material, compound, mixture or preparation which contains
393 any quantity or salt of the following substances combined with one or more
394 active medicinal ingredients:

- 395 a. Amobarbital;
- 396 b. Secobarbital;
- 397 c. Pentobarbital;

398 (b) Any suppository dosage form containing any quantity or salt of
399 the following:

- 400 a. Amobarbital;
- 401 b. Secobarbital;
- 402 c. Pentobarbital;

403 (c) Any substance which contains any quantity of a derivative of
404 barbituric acid or its salt;

- 405 (d) Chlorhexadol;
- 406 (e) Embutramide;

407 (f) Gamma hydroxybutyric acid and its salts, isomers, and salts of
408 isomers contained in a drug product for which an application has been
409 approved under Section 505 of the federal Food, Drug, and Cosmetic Act;

410 (g) Ketamine, its salts, isomers, and salts of isomers;

411 (h) Lysergic acid;

412 (i) Lysergic acid amide;

413 (j) Methyprylon;

414 (k) Sulfondiethylmethane;

415 (l) Sulfonethylmethane;

- 416 (m) Sulfonmethane;
- 417 (n) Tiletamine and zolazepam or any salt thereof;
- 418 (3) Nalorphine;
- 419 (4) Any material, compound, mixture, or preparation containing
- 420 limited quantities of any of the following narcotic drugs or their salts:
- 421 (a) Not more than 1.8 grams of codeine per one hundred milliliters
- 422 or not more than ninety milligrams per dosage unit, with an equal or
- 423 greater quantity of an isoquinoline alkaloid of opium;
- 424 (b) Not more than 1.8 grams of codeine per one hundred milliliters
- 425 or not more than ninety milligrams per dosage unit with one or more active,
- 426 nonnarcotic ingredients in recognized therapeutic amounts;
- 427 (c) Not more than three hundred milligrams of hydrocodone per one
- 428 hundred milliliters or not more than fifteen milligrams per dosage unit,
- 429 with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
- 430 (d) Not more than three hundred milligrams of hydrocodone per one
- 431 hundred milliliters or not more than fifteen milligrams per dosage unit,
- 432 with one or more active nonnarcotic ingredients in recognized therapeutic
- 433 amounts;
- 434 (e) Not more than 1.8 grams of dihydrocodeine per one hundred
- 435 milliliters or not more than ninety milligrams per dosage unit, with one or
- 436 more active nonnarcotic ingredients in recognized therapeutic amounts;
- 437 (f) Not more than three hundred milligrams of ethylmorphine per
- 438 one hundred milliliters or not more than fifteen milligrams per dosage unit,
- 439 with one or more active, nonnarcotic ingredients in recognized therapeutic
- 440 amounts;
- 441 (g) Not more than five hundred milligrams of opium per one hundred
- 442 milliliters or per one hundred grams or not more than twenty-five
- 443 milligrams per dosage unit, with one or more active nonnarcotic ingredients
- 444 in recognized therapeutic amounts;
- 445 (h) Not more than fifty milligrams of morphine per one hundred
- 446 milliliters or per one hundred grams, with one or more active, nonnarcotic
- 447 ingredients in recognized therapeutic amounts;
- 448 (5) Any material, compound, mixture, or preparation containing any
- 449 of the following narcotic drugs or their salts, as set forth in subdivision (6)
- 450 of this subsection; buprenorphine;
- 451 (6) Anabolic steroids. Any drug or hormonal substance, chemically

452 and pharmacologically related to testosterone (other than estrogens,
453 progestins, corticosteroids, and dehydroepiandrosterone) that promotes
454 muscle growth, except an anabolic steroid which is expressly intended for
455 administration through implants to cattle or other nonhuman species and
456 which has been approved by the Secretary of Health and Human Services
457 for that administration. If any person prescribes, dispenses, or distributes
458 such steroid for human use, such person shall be considered to have
459 prescribed, dispensed, or distributed an anabolic steroid within the
460 meaning of this subdivision. Unless specifically excepted or unless listed
461 in another schedule, any material, compound, mixture or preparation
462 containing any quantity of the following substances, including its salts,
463 esters and ethers:

- 464 (a) $3\beta,17$ -dihydroxy-5 α -androstane;
- 465 (b) 3 $\alpha,17\beta$ -dihydroxy-5 α -androstane;
- 466 (c) 5 α -androstan-3,17-dione;
- 467 (d) 1-androstenediol ($3\beta,17\beta$ -dihydroxy-5 α -androst-1-ene);
- 468 (e) 1-androstenediol (3 $\alpha,17\beta$ -dihydroxy-5 α -androst-1-ene);
- 469 (f) 4-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-4-ene);
- 470 (g) 5-androstenediol ($3\beta,17\beta$ -dihydroxy-androst-5-ene);
- 471 (h) 1-androstenedione ([5 α]-androst-1-en-3,17-dione);
- 472 (i) 4-androstenedione (androst-4-en-3,17-dione);
- 473 (j) 5-androstenedione (androst-5-en-3,17-dione);
- 474 (k) Bolasterone (7 α , 17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);
- 475 (l) Boldenone (17 β -hydroxyandrost-1,4,-diene-3-one);
- 476 (m) Boldione;
- 477 (n) Calusterone (7 β , 17 α -dimethyl-17 β -hydroxyandrost-4-en-3-one);
- 478 (o) Clostebol (4-chloro-17 β -hydroxyandrost-4-en-3-one);
- 479 (p) Dehydrochloromethyltestosterone(4-chloro-17 β -hydroxy-17 α -
480 methyl-androst-1,4-dien-3-one);
- 481 (q) Desoxymethyltestosterone;
- 482 (r) ?1-dihydrotestosterone (a.k.a. '1-testosterone')(17 β -hydroxy-5 α -
483 androst-1-en-3-one);
- 484 (s) 4-dihydrotestosterone (17 β -hydroxy-androstan-3-one);
- 485 (t) Drostanolone (17 β -hydroxy-2 α -methyl-5 α -androstan-3-one);
- 486 (u) Ethylestrenol (17 α -ethyl-17 β -hydroxyestr-4-ene);
- 487 (v) Fluoxymesterone (9-fluoro-17 α -methyl-11 $\beta,17\beta$ -dihydroxyandrost

- 488 -4-en-3-one);
- 489 (w) Formebolone (2-formyl-17a-methyl-11a,17 β -dihydroxyandrost-
- 490 1,4-dien-3-one);
- 491 (x) Furazabol (17a-methyl-17 β -hydroxyandrostando[2,3-c]-furazan);
- 492 (y) 13 β -ethyl-17 β -hydroxygon-4-en-3-one;
- 493 (z) 4-hydroxytestosterone (4,17 β -dihydroxy-androst-4-en-3-one);
- 494 (aa) 4-hydroxy-19-nortestosterone (4,17 β -dihydroxy-estr-4-en-3-one);
- 495 (bb) Mestanolone (17a-methyl-17 β -hydroxy-5-androstan-3-one);
- 496 (cc) Mesterolone (1a-methyl-17 β -hydroxy-[5a]-androstan-3-one);
- 497 (dd) Methandienone (17a-methyl-17 β -hydroxyandrost-1,4 -dien-3-
- 498 one);
- 499 (ee) Methandriol (17a-methyl-3 β ,17 β -dihydroxyandrost-5-ene);
- 500 (ff) Methenolone (1-methyl-17 β -hydroxy-5a-androst-1-en-3-one);
- 501 (gg) 17a-methyl-3 β ,17 β -dihydroxy-5a-androstane);
- 502 (hh) 17a-methyl-3a,17 β -dihydroxy-5a-androstane);
- 503 (ii) 17a-methyl-3 β ,17 β -dihydroxyandrost-4-ene;
- 504 (jj) 17a-methyl-4-hydroxynandrolone (17a-methyl-4-hydroxy-17 β -
- 505 hydroxyestr-4-en-3-one);
- 506 (kk) Methyldienolone (17a-methyl-17 β -hydroxyestra-4,9(10)-dien-3
- 507 -one);
- 508 (ll) Methyltrienolone (17a-methyl-17 β -hydroxyestra-4,9-11-trien-3
- 509 -one);
- 510 (mm) Methyltestosterone (17a-methyl-17 β -hydroxyandrost-4-en-3-
- 511 one);
- 512 (nn) Mibolerone (7a,17a-dimethyl-17 β -hydroxyestr-4-en-3-one);
- 513 (oo) 17a-methyl-17 β -dihydrotestosterone (17 β -hydroxy-17a-methyl-5a
- 514 -androst-1-en-3-one) (a.k.a. '17-a-methyl-1-testosterone');
- 515 (pp) Nandrolone (17 β -hydroxyestr-4-ene-3-one);
- 516 (qq) 19-nor-4-androstenediol (3 β ,17 β -dihydroxyestr-4-ene);
- 517 (rr) 19-nor-4-androstenediol (3a,17 β -dihydroxyestr-4-ene);
- 518 (ss) 19-nor-4,9(10)-androstadienedione;
- 519 (tt) 19-nor-5-androstenediol (3 β ,17 β -dihydroxyestr-5-ene);
- 520 (uu) 19-nor-5-androstenediol (3a,17 β -dihydroxyestr-5-ene);
- 521 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
- 522 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
- 523 (xx) Norbolethone (13 β ,17a-diethyl-17 β -hydroxygon-4-en-3-one);

- 524 (yy) Norclostebol (4-chloro-17 β -hydroxyestr-4-en-3-one);
525 (zz) Norethandrolone (17a-ethyl-17 β -hydroxyestr-4-en-3-one);
526 (aaa) Normethandrolone (17a-methyl-17 β -hydroxyestr-4-en-3-one);
527 (bbb) Oxandrolone (17a-methyl-17 β -hydroxy-2-oxa-[5a]-androstan-
528 3-one);
529 (ccc) Oxymesterone (17a-methyl-4,17 β -dihydroxyandrost-4-en-3-one);
530 (ddd) Oxymethalone (17a-methyl-2-hydroxymethylene-17 β -hydroxy
531 -[5a]-androstan-3-one);
532 (eee) Stanozolol (17a-methyl-17 β -hydroxy-[5a]-androst-2-eno[3,2-c]
533 -pyrazole);
534 (fff) Stenbolone (17 β -hydroxy-2-methyl-[5a]-androst-1-en-3-one);
535 (ggg) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-
536 17-oic acid lactone);
537 (hhh) Testosterone (17 β -hydroxyandrost-4-en-3-one);
538 (iii) Tetrahydrogestrinone (13 β ,17a-diethyl-17 β -hydroxygon-4,9,11
539 -trien-3-one);
540 (jjj) Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one);
541 (kkk) Any salt, ester, or ether of a drug or substance described or
542 listed in this subdivision, except an anabolic steroid which is expressly
543 intended for administration through implants to cattle or other nonhuman
544 species and which has been approved by the Secretary of Health and Human
545 Services for that administration;
- 546 (7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft
547 gelatin capsule in a United States Food and Drug Administration approved
548 drug product;
- 549 (8) The department of health and senior services may except by rule
550 any compound, mixture, or preparation containing any stimulant or
551 depressant substance listed in subdivisions (1) and (2) of this subsection
552 from the application of all or any part of sections 195.010 to 195.320 if the
553 compound, mixture, or preparation contains one or more active medicinal
554 ingredients not having a stimulant or depressant effect on the central
555 nervous system, and if the admixtures are included therein in
556 combinations, quantity, proportion, or concentration that vitiate the
557 potential for abuse of the substances which have a stimulant or depressant
558 effect on the central nervous system.
- 559 7. The department of health and senior services shall place a

560 substance in Schedule IV if it finds that:

561 (1) The substance has a low potential for abuse relative to
562 substances in Schedule III;

563 (2) The substance has currently accepted medical use in treatment
564 in the United States; and

565 (3) Abuse of the substance may lead to limited physical dependence
566 or psychological dependence relative to the substances in Schedule III.

567 8. The controlled substances listed in this subsection are included
568 in Schedule IV:

569 (1) Any material, compound, mixture, or preparation containing any
570 of the following narcotic drugs or their salts calculated as the free
571 anhydrous base or alkaloid, in limited quantities as set forth below:

572 (a) Not more than one milligram of difenoxin and not less than
573 twenty-five micrograms of atropine sulfate per dosage unit;

574 (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl
575 -3-methyl-2-propionoxybutane);

576 (c) Any of the following limited quantities of narcotic drugs or their
577 salts, which shall include one or more nonnarcotic active medicinal
578 ingredients in sufficient proportion to confer upon the compound, mixture
579 or preparation valuable medicinal qualities other than those possessed by
580 the narcotic drug alone:

581 a. Not more than two hundred milligrams of codeine per one hundred
582 milliliters or per one hundred grams;

583 b. Not more than one hundred milligrams of dihydrocodeine per one
584 hundred milliliters or per one hundred grams;

585 c. Not more than one hundred milligrams of ethylmorphine per one
586 hundred milliliters or per one hundred grams;

587 (2) Any material, compound, mixture or preparation containing any
588 quantity of the following substances, including their salts, isomers, and
589 salts of isomers whenever the existence of those salts, isomers, and salts of
590 isomers is possible within the specific chemical designation:

591 (a) Alprazolam;

592 (b) Barbital;

593 (c) Bromazepam;

594 (d) Camazepam;

595 (e) Chloral betaine;

- 596 (f) Chloral hydrate;
597 (g) Chlordiazepoxide;
598 (h) Clobazam;
599 (i) Clonazepam;
600 (j) Clorazepate;
601 (k) Clotiazepam;
602 (l) Cloxazolam;
603 (m) Delorazepam;
604 (n) Diazepam;
605 (o) Dichloralphenazone;
606 (p) Estazolam;
607 (q) Ethchlorvynol;
608 (r) Ethinamate;
609 (s) Ethyl loflazepate;
610 (t) Fludiazepam;
611 (u) Flunitrazepam;
612 (v) Flurazepam;
613 (w) Fospropofol;
614 (x) Halazepam;
615 (y) Haloxazolam;
616 (z) Ketazolam;
617 (aa) Loprazolam;
618 (bb) Lorazepam;
619 (cc) Lormetazepam;
620 (dd) Mebutamate;
621 (ee) Medazepam;
622 (ff) Meprobamate;
623 (gg) Methohexital;
624 (hh) Methylphenobarbital (mephobarbital);
625 (ii) Midazolam;
626 (jj) Nimetazepam;
627 (kk) Nitrazepam;
628 (ll) Nordiazepam;
629 (mm) Oxazepam;
630 (nn) Oxazolam;
631 (oo) Paraldehyde;

- 632 (pp) Petrichloral;
- 633 (qq) Phenobarbital;
- 634 (rr) Pinazepam;
- 635 (ss) Prazepam;
- 636 (tt) Quazepam;
- 637 (uu) Temazepam;
- 638 (vv) Tetrazepam;
- 639 (ww) Triazolam;
- 640 (xx) Zaleplon;
- 641 (yy) Zolpidem;
- 642 (zz) Zopiclone;
- 643 (3) Any material, compound, mixture, or preparation which contains
- 644 any quantity of the following substance including its salts, isomers and
- 645 salts of isomers whenever the existence of such salts, isomers and salts of
- 646 isomers is possible: fenfluramine;
- 647 (4) Any material, compound, mixture or preparation containing any
- 648 quantity of the following substances having a stimulant effect on the
- 649 central nervous system, including their salts, isomers and salts of isomers:
- 650 (a) Cathine ((+)-norpseudoephedrine);
- 651 (b) Diethylpropion;
- 652 (c) Fencamfamin;
- 653 (d) Fenproporex;
- 654 (e) Mazindol;
- 655 (f) Mefenorex;
- 656 (g) Modafinil;
- 657 (h) Pemoline, including organometallic complexes and chelates
- 658 thereof;
- 659 (i) Phentermine;
- 660 (j) Pipradrol;
- 661 (k) Sibutramine;
- 662 (l) SPA ((-)-1-dimethylamino-1,2-diphenylethane);
- 663 (5) Any material, compound, mixture or preparation containing any
- 664 quantity of the following substance, including its salts:
- 665 (a) butorphanol;
- 666 (b) pentazocine;
- 667 (6) Ephedrine, its salts, optical isomers and salts of optical isomers,

668 when the substance is the only active medicinal ingredient;

669 (7) The department of health and senior services may except by rule
670 any compound, mixture, or preparation containing any depressant
671 substance listed in subdivision (1) of this subsection from the application
672 of all or any part of sections 195.010 to 195.320 and sections 579.015 to
673 579.086 if the compound, mixture, or preparation contains one or more
674 active medicinal ingredients not having a depressant effect on the central
675 nervous system, and if the admixtures are included therein in
676 combinations, quantity, proportion, or concentration that vitiate the
677 potential for abuse of the substances which have a depressant effect on the
678 central nervous system.

679 9. The department of health and senior services shall place a
680 substance in Schedule V if it finds that:

681 (1) The substance has low potential for abuse relative to the
682 controlled substances listed in Schedule IV;

683 (2) The substance has currently accepted medical use in treatment
684 in the United States; and

685 (3) The substance has limited physical dependence or psychological
686 dependence liability relative to the controlled substances listed in Schedule
687 IV.

688 10. The controlled substances listed in this subsection are included
689 in Schedule V:

690 (1) Any compound, mixture or preparation containing any of the
691 following narcotic drugs or their salts calculated as the free anhydrous base
692 or alkaloid, in limited quantities as set forth below, which also contains one
693 or more nonnarcotic active medicinal ingredients in sufficient proportion to
694 confer upon the compound, mixture or preparation valuable medicinal
695 qualities other than those possessed by the narcotic drug alone:

696 (a) Not more than two and five-tenths milligrams of diphenoxylate
697 and not less than twenty-five micrograms of atropine sulfate per dosage
698 unit;

699 (b) Not more than one hundred milligrams of opium per one hundred
700 milliliters or per one hundred grams;

701 (c) Not more than five-tenths milligram of difenoxin and not less
702 than twenty-five micrograms of atropine sulfate per dosage unit;

703 (2) Any material, compound, mixture or preparation which contains

704 any quantity of the following substance having a stimulant effect on the
705 central nervous system including its salts, isomers and salts of isomers:
706 pyrovalerone;

707 (3) Any compound, mixture, or preparation containing any detectable
708 quantity of pseudoephedrine or its salts or optical isomers, or salts of
709 optical isomers or any compound, mixture, or preparation containing any
710 detectable quantity of ephedrine or its salts or optical isomers, or salts of
711 optical isomers;

712 (4) Unless specifically exempted or excluded or unless listed in
713 another schedule, any material, compound, mixture, or preparation which
714 contains any quantity of the following substances having a depressant
715 effect on the central nervous system, including its salts:

716 (a) Lacosamide;

717 (b) Pregabalin.

718 11. If any compound, mixture, or preparation as specified in
719 subdivision (3) of subsection 10 of this section is dispensed, sold, or
720 distributed in a pharmacy without a prescription:

721 (1) All packages of any compound, mixture, or preparation
722 containing any detectable quantity of pseudoephedrine, its salts or optical
723 isomers, or salts of optical isomers or ephedrine, its salts or optical isomers,
724 or salts of optical isomers, shall be offered for sale only from behind a
725 pharmacy counter where the public is not permitted, and only by a
726 registered pharmacist or registered pharmacy technician; and

727 (2) Any person purchasing, receiving or otherwise acquiring any
728 compound, mixture, or preparation containing any detectable quantity of
729 pseudoephedrine, its salts or optical isomers, or salts of optical isomers or
730 ephedrine, its salts or optical isomers, or salts of optical isomers shall be
731 at least eighteen years of age; and

732 (3) The pharmacist, intern pharmacist, or registered pharmacy
733 technician shall require any person, prior to such person's purchasing,
734 receiving or otherwise acquiring such compound, mixture, or preparation
735 to furnish suitable photo identification that is issued by a state or the
736 federal government or a document that, with respect to identification, is
737 considered acceptable and showing the date of birth of the person;

738 (4) The seller shall deliver the product directly into the custody of
739 the purchaser.

740 12. Pharmacists, intern pharmacists, and registered pharmacy
741 technicians shall implement and maintain an electronic log of each
742 transaction. Such log shall include the following information:

- 743 (1) The name, address, and signature of the purchaser;
744 (2) The amount of the compound, mixture, or preparation purchased;
745 (3) The date and time of each purchase; and
746 (4) The name or initials of the pharmacist, intern pharmacist, or
747 registered pharmacy technician who dispensed the compound, mixture, or
748 preparation to the purchaser.

749 13. Each pharmacy shall submit information regarding sales of any
750 compound, mixture, or preparation as specified in subdivision (3) of
751 subsection 10 of this section in accordance with transmission methods and
752 frequency established by the department by regulation;

753 14. No person shall dispense, sell, purchase, receive, or otherwise
754 acquire quantities greater than those specified in this chapter.

755 15. All persons who dispense or offer for sale pseudoephedrine and
756 ephedrine products in a pharmacy shall ensure that all such products are
757 located only behind a pharmacy counter where the public is not permitted.

758 16. The penalties for a knowing or reckless violation of the
759 provisions of subsections 11 to 15 of this section are found in section
760 579.060.

761 17. The scheduling of substances specified in subdivision (3) of
762 subsection 10 of this section and subsections 11, 12, 14, and 15 of this
763 section shall not apply to any compounds, mixtures, or preparations that
764 are in liquid or liquid-filled gel capsule form or to any compound, mixture,
765 or preparation specified in subdivision (3) of subsection 10 of this section
766 which must be dispensed, sold, or distributed in a pharmacy pursuant to a
767 prescription.

768 18. The manufacturer of a drug product or another interested party
769 may apply with the department of health and senior services for an
770 exemption from this section. The department of health and senior services
771 may grant an exemption by rule from this section if the department finds
772 the drug product is not used in the illegal manufacture of
773 methamphetamine or other controlled or dangerous substances. The
774 department of health and senior services shall rely on reports from law
775 enforcement and law enforcement evidentiary laboratories in determining

776 if the proposed product can be used to manufacture illicit controlled
777 substances.

778 19. The department of health and senior services shall revise and
779 republish the schedules annually.

780 20. The department of health and senior services shall promulgate
781 rules under chapter 536 regarding the security and storage of Schedule V
782 controlled substances, as described in subdivision (3) of subsection 10 of
783 this section, for distributors as registered by the department of health and
784 senior services.

785 21. Logs of transactions required to be kept and maintained by this
786 section and section 195.417 shall create a rebuttable presumption that the
787 person whose name appears in the logs is the person whose transactions are
788 recorded in the logs.

✓

Bill

Copy